Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "in explicit technical detail"

TPL and PTSC contribute equally to PDS to cover expenses of litigation and licensing.

People don't know if "ongoing royalties were on the table", thats just it.

Negotiations may change depending on where litigation takes you. To rule out royalties as a precondition to settlement is not likely in my opinion.

My thinking is we got royalties out of the deal, although we will probably never know for sure or how much, but the next Q may help to some degree is we see decent equity earnings and much-reduced expenses.

I will try to not let my current disappointment with the share price decline overwhelm the fact that the MMP has substantial value.

Share
New Message
Please login to post a reply